Bioenvision About
Bioenvision: Bioenvision is a product-focused biopharmaceutical
company with two approved cancer therapeutics. The FDA recently approved their
lead cancer product, clofarabine, for the treatment of pediatric acute
lymphoblastic leukemia, or ALL.Genzyme Corporation, their co-development partner,
currently holds marketing rights in the U.S. and Canada for clofarabine for all
cancer indications and controls U.S. development of clofarabine in these indications.
Genzyme is marketing clofarabine under the brand name Clolar in the U.S.
Modrenal is approved in the U.K. for the treatment of post-menopausal advanced
breast cancer following relapse to initial hormone therapy. More
on Bioenvision:
Key
Statistics for Bioenvision
Modrenal Prostate
Cancer Virostat Chronic
Hepatitis C Clofarabine
(CLOLAR) Solid
Tumors
Basic
Chart for Bioenvision